Jinyao Pharmaceutical Company: Subsidiary Hubei Jinyao has obtained the registration certificate for the injection of metoclopramide hydrochloride.

Jinyao Pharmaceutical announced that its subsidiary, Hubei Jinyao, has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the metoclopramide hydrochloride injection. Metoclopramide hydrochloride injection is a antiemetic drug mainly used for chemotherapy, radiotherapy, surgery, head trauma, sequelae of brain trauma, seasickness, airsickness, and drug-induced vomiting. It is used for symptomatic treatment of nausea and vomiting symptoms in various diseases such as acute gastroenteritis, biliary pancreatitis, and uremia. It is also used before diagnostic duodenal intubation to facilitate intubation; for gastrointestinal barium X-ray examination, it can reduce nausea and vomiting reactions and promote the passage of barium. In December 2023, Hubei Jinyao submitted an application for domestic production drug registration and approval to the Drug Evaluation Center of the National Medical Products Administration and was accepted. The Drug Registration Certificate issued by the National Medical Products Administration was obtained in November 2025.